Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases

British Journal of Cancer

Volumn 107, Issue 10, 2012, Pages 1665-1671

  Beuselinck, B ^a,b   Wolter, P ^a   Karadimou, A ^b   Elaidi, R ^c   Dumez, H ^a   Rogiers, A ^a   Van Cann, T ^a   Willems, L ^a   Body, J J ^d   Berkers, J ^a   Van Poppel, H ^a   Lerut, E ^a   Debruyne, P ^e   Paridaens, R ^a   Schoffski P ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Labex Immuno Oncology   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^e NONE   (Belgium)

Author keywords

Bisphosphonates; Bone metastases; Osteonecrosis of the jaw; Outcome; Renal cell carcinoma; Targeted therapy

Indexed keywords

IBANDRONIC ACID; PAMIDRONIC ACID; SORAFENIB; SUNITINIB; ZOLEDRONIC ACID;

ADULT; ADVANCED CANCER; ARTICLE; BELGIUM; BONE METASTASIS; CANCER PATIENT; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; HUMAN; INCIDENCE; JAW OSTEONECROSIS; KIDNEY CARCINOMA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; UNIVERSITY HOSPITAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CARCINOMA, RENAL CELL; DIPHOSPHONATES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NIACINAMIDE; OSTEONECROSIS; PHENYLUREA COMPOUNDS; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRROLES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84869225968     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.385     Document Type: Article

References (29)

1. Ayllon J, Launay-Vacher V, Medioni J, Cros C, Spano JP, Oudard S (2009) Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile? Ann Oncol 20(3): 600-601.
2. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23(34): 8580-8587. (Pubitemid 46211499)
3. Beuselinck B, Oudard S, Rixe O, Wolter P, Blesius A, Ayllon J, Elaidi R, Schöffski P, Barrascout E, Morel A, Escudier B, Lang H, Zucman-Rossi J, Medioni J (2011) 'Negative impact of bone metastasis on outcome in clear cell renal cell carcinoma treated with sunitinib'. Ann Oncol 22(4): 794-800.
4. Bozas G, Allgar V, Greenwood G, Maraveyas A (2011) Osteonecrosis of the jaw in patients treated with sunitinib and zoledronic acid. J Clin Oncol 29(Suppl): Abstract e15116.
5. Christodoulou C, Pervena A, Klouvas G, Galani E, Falagas ME, Tsakalos G, Visvikis A, Nikolakopoulou A, Acholos V, Karapanagiotidis G, Batziou E, Skarlos DV (2009) Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 76(3): 209-211.
6. Clezardin P, Teti A (2007) Bone metastasis: pathogenesis and therapeutic implications. Clin Exp Metastasis 24(8): 599-608. (Pubitemid 50003596)
7. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, TARGET Study Group (2007a) TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2): 125-134. (Pubitemid 46089673)
8. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N, AVOREN Trial investigators (2007b) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 370(9605): 2103-2111. (Pubitemid 350296300)
9. Guarneri V, Miles D, Robert N, Die'ras V, Glaspy J, Smith I, Thomssen C, Biganzoli L, Taran T, Conte P (2010) Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 122(1): 181-188.
10. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, Global ARCC Trial (2007) Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renalcell carcinoma. N Engl J Med 356(22): 2271-2281.
11. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 2006: 106-130.
12. Keizman D, Ish-Shalom M, Pili R, Hammers H, Eisenberger M, Sinibaldi V, Boursi B, Maimon N, Gottfried M, Hayat H, Peer A, Kovel S, Sella A, Berger R, Carducci MA (2012) Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma. Eur J Cancer 48(7): 1031-1037.
13. Lam JS, Leppert JT, Belldegrun AS, Figlin RA (2005) Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol 23(3): 202-212. (Pubitemid 41136043)
14. Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross F, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Child JA, National Cancer Research Institute Haematological Oncology Clinical Study Group (2010) First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): A randomised controlled trial. Lancet 376(9757): 1989-1999.
15. Motzer R, Bacik J, Mazumbar M (2004) Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan Kettering Cancer Center experience. Clin Cancer Res 10(18 Part 2): 6202S-6203S\
16. Motzer R, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17(8): 2530-2540. (Pubitemid 29368255)
17. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A, RECORD-1 Study Group (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116(18): 4256-4265.
18. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A, RECORD-1 Study Group (2008) Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637): 449-456.
19. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2): 115-124. (Pubitemid 46089672)
20. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2): 74-108. (Pubitemid 40372904)
21. Patil S, Figlin R, Hutson T, Michaelson M, Ne'grier S, Kim T, Huang X, Motzer R (2011) Prognostic factors for progression free survival and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 22(2): 295-300.
22. Riechelmann R, Chin S, Wang L, Tannock IF, Berthold DR, Moore MJ, Knox JJ (2008) Sorafenib for metastatic renal cancer: The Princess Margaret experience. Am J Clin Oncol 31(2): 182-187. (Pubitemid 351519171)
23. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman JJ (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21(16): 3150-3157. (Pubitemid 46606297)
24. Saad F, Eastham JA (2010) Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer. Semin Oncol 37(Suppl 1): S38-S44.
25. Saad F, Lipton A (2005) Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU Int 96: 964-969. (Pubitemid 41531396)
26. US National Institutes of Health (2006) Surveillance, epidemiology and end results (SEER) cancer statistics review. Kidney and Renal Pelvis Cancer. 5-year Relative Survival Rates, 1996-2002; http://seer.cancer.gov/cgi-bin/csr/ 1975-2003/search.pl#results (September 2006)\
27. Zaghloul MS, Boutrus R, El-Hossieny H, Kader YA, El-Attar I, Nazmy M (2010) A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol 15(4): 382-389.
28. Zarogoulidis K, Boutsikou E, Zarogoulidis P, Eleftheriadou E, Kontakiotis T, Lithoxopoulou H, Tzanakakis G, Kanakis I, Karamanos NK (2009) The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer 125(7): 1705-1709.
29. Zekri J, Ahmed N, Coleman RE, Hancock BW (2001) The skeletal metastatic complications of renal cell carcinoma. Int J Oncol 19: 379-382